Our Tailored Services
Drug Development Companies
Indication Screen & Expansion
An EU biotech develops clinical-stage oncology assets & aims to explore potential indication expansion strategies screening patient niches with highest unmet need.
Case Study
Biological targets play a functional role in the pathophysiology of multiple diseases. Our team creates a target biology or technology-specific database by integrating disease genomics, epidemiology, animal models, scientific literature and more. This allows to systemically rank associated indications across scientific, clinical and commercial dimensions. Next, rigorous deep-dives ensure actionable recommendations.
Approach by NicinBio Strategy
Target Selection & Prioritization
A US biotech aims to utilize its proprietary drug delivery approach for diabetic retinopathy but needs to screen for appropriate biologic targets.
Case Study
We apply an unbiased database approach generating an option space of biological targets involved in diabetic retinopathy. Next, we rank the option space on several dimensions incl. scientific rationale, role in disease, applicability of your approach, competition and transformative potential. Finally, we perform manual high-level analysis of the top ranked targets. The firm goes on to apply their proprietary technology on a relevant biologic target.
Approach by NicinBio Strategy
Competitive Intelligence
A US academic spin-off developing gene therapies for rare diseases needs a robust market analysis for strategic positioning and to stress their value to early investors.
Case Study
We perform a semi-automated search in our proprietary database with ∼30,000 drugs, deriving a comprehensive list of potential competitors. We can focus on multiple criteria, including biologic target, modality and indication. In a next step, we screen the list to generate a curated space of relevant competitors. Finally, we apply a proprietary scoring approach, resulting in a ranked competitive landscape, informing strategic decisions.
Approach by NicinBio Strategy
Asset Search & Evaluation
A US biopharma company specializing in neurodegenerative disease treatments aims for novel therapeutic assets to enhance its preclinical pipeline.
Case Study
We generate an option space applying customized filters to our proprietary database of ∼30,000 drugs and ∼10,000 companies. Next, we rank the option space according to your firms strategic focus resulting in prioritized candidates. In a high-level analysis step, we screen the top ranked drugs/companies and generate one-pager summaries. In a final step, we dive deep into prioritized options to evaluate key risks and high potentials.
Approach by NicinBio Strategy
Scientific Due Diligence
A US pharma company intends to partner a preclinical asset requiring deep scientific evaluation of potential risks, including PoS assessment.
Case Study
We support scientific/technical and commercial due diligence processes, ensuring a meticulous assessment of potential risks. Our team evaluates the mechanism of action, focuses on scientific rationale, ranks relevant competitors, compares development timelines and regulatory requirements and models market sizes and commercial opportunities. The output supports the team to guide their investment hypothesis.
Approach by NicinBio Strategy
Technology Landscapes
An EU pharma client aims to update the validation status and potential of a technology to prioritize fields for partnering and internal development.
Case Study
We track dedicated research funding, scientific publications, patent applications, clinical trials, investments in start-ups, partnering deals and more. Our approach dives deep beneath the surface of IP and publication activity, delivering unique insights that give our clients an edge, years before technologies reach the hype phase. Generated landscape maps can be focused on distinct filters and dimensions based on the client’s strategy.
Approach by NicinBio Strategy
Out-Licensing Support
An EU biotech client intends to present latest data at the upcoming J.P. Morgan Conference to explore partnerships for their early-stage immuno-oncology assets.
Case Study
We support by strategically positioning the client’s assets. Our output includes highlighting the unmet need and commercial potential in the niche of interest, demonstrating the competitive advantage and unique selling point of the client’s assets, summarizing supporting data from the literature and preclinical data from the client and drafting an overview of synergistic companies with potential interest for partnerships.
Approach by NicinBio Strategy
Development Strategy
An US biotech clients aims to initiate clinical investigation of a novel antibody-drug conjugate in a rare indication.
Case Study
In the earliest phases of clinical development, we provide expertise to identify patient settings with the highest unmet need, evaluate potential combination strategies and to achieve proof-of-concept for their approach. In later stages, we support by systemically reviewing the competitive field, trial designs adopted by competitors and benchmarks for patient enrollment, trial duration and endpoint measures.
Approach by NicinBio Strategy
